Annexon Biosciences (ANNX)
NASDAQ:ANNX
Annexon Biosciences Financial Statements
Annexon Biosciences Financial Overview
Annexon Biosciences's market cap is currently ―. The company's EPS TTM is $-3.63; its P/E ratio is -1.07; Annexon Biosciences is scheduled to report earnings on August 15, 2022, and the estimated EPS forecast is $-0.94. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ ― | $ ― | $ ― | $ ― | $ ― |
| EBIT | $ -35.43M | $ -37.46M | $ -35.68M | $ -31.37M | $ -26.20M |
| EBITDA | $ -34.91M | $ -36.95M | $ -35.12M | $ -30.84M | $ -25.66M |
| Net Income Common Stockholders | $ -35.37M | $ -37.37M | $ -35.60M | $ -31.29M | $ -26.06M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 206.66M | $ 242.72M | $ 271.37M | $ 302.39M | $ 326.65M |
| Total Assets | $ 250.57M | $ 287.04M | $ 310.16M | $ 331.78M | $ 333.12M |
| Total Debt | $ 63.00K | $ 26.41M | $ 34.10M | $ 34.66M | $ 33.76M |
| Net Debt | $ -206.60M | $ -216.30M | $ -237.26M | $ -267.72M | $ -292.89M |
| Total Liabilities | $ 49.95M | $ 55.13M | $ 45.68M | $ 36.45M | $ 11.64M |
| Stockholders Equity | $ 200.61M | $ 231.91M | $ 264.48M | $ 295.33M | $ 321.48M |
| Cash Flow | |||||
| Free Cash Flow | $ -35.50M | $ -29.18M | $ -30.48M | $ -24.63M | $ -23.47M |
| Operating Cash Flow | $ -30.29M | $ -28.32M | $ -29.71M | $ -24.63M | $ -23.44M |
| Investing Cash Flow | $ 68.25M | $ 33.70M | $ -1.28M | $ -83.07M | $ -37.58M |
| Financing Cash Flow | $ 19.00K | $ 948.00K | $ -73.00K | $ 652.00K | $ 268.00K |